Investor Presentaiton

Clinical development in multiple cancers Clarity's products are progressing through clinical development in the US and Australia. Clinical development pipeline as of 27 May 2022 Indication Product Application Current Trial Discovery Preclinical Phase I Phase 2 Phase 3 Next Milestone SAR-bisPSMA Theranostic mCRPC SECURE SAR-bisPSMA Diagnostic in pre-radical PROPELLER prostatectomy Prostate Cancer SAR-bisPSMA Diagnostic in BCR PCa COBRA Diagnostic in SAR-BBN BCR PCa SAR-BBN Theranostic SARTATE™M Theranostic CL04 Neuroblastoma SARTATE™M Diagnostic NETS SARTATE™M Diagnostic DISC Pan cancer (GRPr positive tumours) SAR-BBN Diagnostic Undisclosed Undisclosed SAR Discovery Platform Undisclosed Undisclosed CLARITY 2014 MEIE 332 Current progress 12 month progress :: First therapy treatment PROPELLER recruitment complete 50% recruitment in COBRA Open IND for 64Cu SAR- BBN Open IND for 67 CU SAR- BBN Advance to Cohort 3 Open IND for NB diagnostic 50% recruitment in DISCO First patient in GRPr positive tumour Note clinical development pipeline is indicative only, subject to review. All US studies are conducted under IND 9

View entire presentation